SEC Form 4 · accession 0001104659-26-088371
Yarrow Bioscience, Inc. · YARW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mona Ashiya
Director
Period of report
Jul 27, 2026
Accepted (ET)
Jul 29, 2026 · 9:36 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001566044
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $28.56 | Jul 27, 2026 | A | 15,435 | A | — | Jul 27, 2036 | Common Stock | 15,435 | 15,435 | D |
Explanation of responses
- F1This option represents a right to purchase 15,435 shares of the Issuer's common stock, which vests in full on the earlier of (i) July 27, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the recipient's continued service to the Issuer.
- F2Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments X, LP.